质子碳离子放疗对比调强放疗通过降低胸椎与主动脉剂量减少非小细胞肺癌重度淋巴细胞减少
研究纳入343例接受根治性调强放疗(IMRT)或质子碳离子放疗(PCIRT)的非小细胞肺癌(NSCLC)患者,比较重度淋巴细胞减少(SRL,绝对淋巴细胞计数≤0.5×10³ cells/μL)的差异。PCIRT组较IMRT组更少发生SRL(P<.001),IMRT为SRL独立危险因素(P=.004);SRL与更差总生存相关(中位生存29.2个月 vs 15.0个月,P=.046)。胸椎V5(P=.002)和主动脉V5(P=.026)为SRL独立风险预测因子。
要点
- PCIRT组较IMRT组更少发生重度淋巴细胞减少(P<.001)。
- IMRT为SRL独立危险因素(P=.004),放疗前低ALC(P=.030)和大PTV(P=.002)亦为独立危险因素。
- SRL组中位生存15.0个月 vs 非SRL组29.2个月(P=.046)。
核心结论
- 与IMRT相比,PCIRT可能通过限制胸椎和主动脉剂量降低SRL发生率,且SRL与NSCLC患者不良结局相关。
研究设计与样本
- 收集343例接受根治性IMRT或PCIRT的NSCLC患者的临床和剂量学参数,并进行倾向性评分匹配。
主要发现
- PCIRT组较IMRT组更少发生SRL(P<.001)。
- SRL组较非SRL组与更差OS显著相关,中位生存时间29.2个月 vs 15.0个月(P=.046)。
- IMRT为SRL独立危险因素(P=.004),放疗前较低ALC(P=.030)和较大PTV(P=.002)亦为显著独立危险因素。
- PCIRT中多数危及器官剂量学参数低于IMRT(P<.001)。
- 将剂量学参数加入回归模型后,胸椎V5(P=.002)和主动脉V5(P=.026)被确定为SRL独立风险预测因子。
关键数值与推荐
- SRL定义为绝对淋巴细胞计数≤0.5×10³ cells/μL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lymphopenia is a common adverse effect of radiation therapy (RT). Little is known about the difference in lymphopenia between intensity modulated (photon) radiation therapy (IMRT) and proton and carbon ion radiation therapy (PCIRT). This study aimed to investigate lymphopenia differences between IMRT and PCIRT in non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Clinical and dosimetric parameters were collected from 343 patients who received definitive IMRT or PCIRT for NSCLC. Severe lymphopenia (SRL) was defined as an absolute lymphocyte count (ALC) ≤0.5 × 103 cells/μL. Overall survival (OS) was analyzed using the Kaplan-Meier method. Propensity score matching was performed between the IMRT and PCIRT groups. Least absolute shrinkage and selection operator analysis was used to select appropriate dosimetric parameters. Univariate and multivariate logistic regression analyses were conducted to identify the predictors of SRL. RESULTS: Compared with the IMRT group, the PCIRT group was less likely to develop SRL (P < .001). Compared with the non-SRL group, the SRL group showed significant association with poorer OS, with a median survival time of 29.2 versus 15.0 months (P = .046). IMRT was an independent risk factor of SRL (P = .004). A lower ALC before RT (P = .030) and larger planning target volume (PTV) (P = .002) were also significant independent risk factors for SRL. Moreover, the majority of dosimetric parameters of organs at risk in PCIRT were lower than those in IMRT (P < .001). Thoracic vertebra V5 (P = .002) and aorta V5 (P = .026) were identified as independent risk predictors of SRL after adding dosimetric parameters to the regression model. CONCLUSIONS: Compared with IMRT, PCIRT could reduce SRL incidence, possibly by limiting thoracic vertebra and aortic doses, and SRL was associated with poor outcomes in patients with NSCLC.
引用
- Li Y, Fan X, Yu Q, et al. Proton and Carbon Ion Radiation Therapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Doses in Non-Small Cell Lung Cancer Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022. PMID: 36586495. doi:10.1016/j.ijrobp.2022.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。